Zimmerman Chiropractic Ps Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2625 Martin Way E Ste A, Olympia, WA 98506 Phone: 360-352-5145 |
Vanquaethem Chiropractic Clinic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1645 Cooper Point Rd Sw, Olympia, WA 98502 Phone: 360-943-6206 Fax: 360-943-6276 |
Dr. Chong Ryan Yun, D.C. Chiropractor - Nutrition Medicare: Not Enrolled in Medicare Practice Location: 7914 Martin Way E, Ste #8, Olympia, WA 98516 Phone: 360-339-7177 Fax: 360-339-7177 |
Dr. Aaron J Fitzpatrick, DC LMP Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1700 Cooper Point Rd Sw, Suite A 1, Olympia, WA 98502 Phone: 360-754-2915 Fax: 360-754-6919 |
News Archive
A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center.
How does the brain determine what matters? According to a new scientific article, a brain structure called the insula is essential for selecting things out of the environment that are "salient" for an individual, and dysfunction of this system is linked to brain disorders such as autism, psychosis and dementia.
New research from the University of Sydney has found the severity of febrile seizures following vaccination is no different to febrile seizures from another cause, such as from a virus, and that the majority of seizures are short-lived, self-resolving and don't require ongoing treatment.
Based on responses to a survey conducted by the National Business Group on Health, large employers are bracing for cost increases and will likely pass the added burden on to their employees.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
› Verified 9 days ago